Abstract
Cisplatin is a highly effective and frequently used drug in the chemotherapy of solid tumors in children, but there is currently no information to guide dosing in children requiring dialysis. Here, we present the case of a 2-year-old boy with end-stage renal disease managed with peritoneal dialysis and requiring cisplatin for a newly diagnosed hepatoblastoma. A pharmacokinetic study was performed to personalize the cisplatin dose with the goal of providing adequate cisplatin exposure and avoiding excessive exposure and toxicity. Accordingly, 25% of the standard cisplatin dose was infused intravenously over 4 h. Serial blood and peritoneal fluid samples were obtained, and free cisplatin levels were subjected to noncompartmental pharmacokinetic analysis. The disposition of free cisplatin was significantly altered as compared to that of normal children. Despite a 75% dose reduction, our patient showed a fourfold increase in free cisplatin exposure (AUC = 64.1 h mcg/mL) compared with the AUC observed in children with normal kidney (15 ± 9 h mcg/mL) function. When a subsequent dose was decreased to 8.7% of the standard dose, the free cisplatin AUC measured 29.7 h mcg/mL and more closely approximated the exposure observed in children with normal kidney function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Loehrer PJ, Einhorn LH (1984) Cisplatin. Ann Intern Med 100:704–713
Zwelling LA (1986) Cisplatinum and new platinum analogs. Cancer Chemotherapy, annual 8. Elsevier, New York, pp 97–116
Reed E, Dabholkar M, Chabner BA (1996) Platinum analogues. Cancer chemotherapy and biotherapy principles and practice. Lippincott-Raven, Philadelphia
LeRoy AF, Lutz RJ, Dedrick RL, Litterst CL, Guarino AM (1979) Pharmacokinetic study of cis-diammine-dichloroplatinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treat Rep 63:59–71
Gormley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25:351–357
Dominici C, Petrucci F, Caroli S, Alimonthi A, Clerico A, Castello MA (1989) A pharmacokinetic study of high dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol 7:100–107
Cvitkovic E (1998) Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24:265–281
Gouyette A, Lemoine R, Adhemar JP, Kleinknecht D, Man NK, Droz JP, Macquet JP (1981) Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep 65:7–8
Tomita M, Kurata H, Aoki Y, Tanaka K, Kazama J (2001) Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 12:485–487
Lee CW, Fabbro J (2005) Administration of cisplatin and etoposide during chronic ambulatory peritoneal dialysis. Clin Oncol 17:667
Berland Y, Bues-Charbit M, Merzouk T, Boutin C, Cano JP, Olmer M (1990) Kinetics of cisplatin in a patient with lung carcinoma on continuous ambulatory peritoneal dialysis. Nephron 54:105–106
Tanabe N, Goto M, Morita H, Gotu T, Inagaki J, Yamanaki N, Kimura K (1991) Pharmacokinetics of cis-diammine-dichlor-platin in a hemodialysis patient. Cancer Invest 9:629–635
Tomita M, Aoki Y, Tanaka K (2004) Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. Clin Pharmacokinet 43:515–527
Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M (2001) Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 57:393–402
Peng B, English MW, Boddy AV, Price L, Wyllie R, Pearson ADJ, Tilby MJ, Newel DR (1997) Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 33:1823–1828
Perilongo G, Shafford E, Plaschkes J, Liver Tumour Study Group of the International Society of Paediatric Oncology (2000) SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 1:94–100
Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, Plaschkes J, Perilongo G, Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL) (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era-recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031–1036
Aaronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, Brown J, Phillips A, Otte JB, Czauderna P, MacKinlay G, Vos A (2007) Predictive value of the pretreatment extent of disease system in hepatoblastoma:results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 20:1245–1252
Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes J, International society of Paediatric Oncology-SIOPEL 2 (2004) Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 40:411–421
McHugh K, Kao S (2003) Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br J Radiol 76:433–436
Bues-Charbit M, Gentet JC, Bernard JL, Breant V, Cano JP, Raybaud C (1987) Continuous Infusion of High-Dose Cisplatin in Children: Pharmacokinetics of Free and Total Platinum. Eur J Cancer Clin Oncol 23:1649–1652
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Sebestyen, J., Garg, U., Lewing, K.B. et al. Cisplatin pharmacokinetics in a child receiving peritoneal dialysis. Pediatr Nephrol 25, 1185–1189 (2010). https://doi.org/10.1007/s00467-009-1420-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1420-6